EGF and cancer: To investigate whether platelets could facilitate the maintenance of this more motile phenotype, we developed an EMT/mesenchymal epithelial transition (MET) model in two of the ovarian cancer cell lines (59M and SKOV3), using epidermal growth factor (EGF) treatment, which was previously shown to upregulate EMT markers, inhibit E-cadherin expression, and promote EMT and cancer cell migration/invasion.